MediWound Ltd. announced on April 2, 2026 that its exclusive North American distributor, Vericel, has been awarded a ten‑year contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $197 million for the enzymatic debridement therapy NexoBrid. The agreement, effective April 1, 2026, establishes a vendor‑managed inventory system and funds the design and validation of a U.S. manufacturing facility.
The contract covers procurement of NexoBrid for the Strategic National Stockpile, supports the development of a room‑temperature stable formulation, and provides a potential expanded indication for blast‑trauma injuries. The base period of the agreement is valued at $35 million, with an initial 12‑month procurement allocation of approximately $10 million for initial procurement and VMI setup.
MediWound’s Q4 2025 revenue of $17 million fell from $20.2 million in 2024, a decline attributed to a U.S. government shutdown and lower product sales to Vericel. Despite the revenue dip, the company’s cash and equivalents rose to $53.6 million from $43.6 million, and it reaffirmed its 2026 revenue guidance of $24–$26 million. The BARDA contract strengthens the company’s financial outlook by adding a de‑risked, long‑term revenue source and supporting future manufacturing and formulation expansion.
In a Q4 2025 earnings call, CEO Ofer Gonen highlighted two growth drivers for 2026: the Phase III VALUE trial of EscharEx and the expanded NexoBrid manufacturing facility now operational. Vericel’s President and CEO Nick Colangelo stated, "We are very pleased to partner with BARDA to support U.S. national preparedness for potential mass casualty events involving severe thermal burns and blast trauma injuries."
The agreement positions MediWound to meet future demand for NexoBrid, supports a new blast‑trauma indication, and provides a recurring revenue stream that underpins the company’s strategic pipeline and long‑term commercial prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.